ArticleBioMedicine2021
Evaluation of Fructosamine 3-kinase and Glyoxalase 1 activity in normal and breast cancer tissues.
Article in BioMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Exosomal MALAT1 promotes the proliferation of esophageal squamous cell carcinoma through glyoxalase 1-dependent methylglyoxal removal.Non-coding RNA research · 2024Article
- Role of the Glyoxalase System in Breast Cancer and Gynecological Cancer-Implications for Therapeutic Intervention: a Review.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is a typical malignancy and the most common in the female and it is the primary reason behind cancer-related deaths of women around the world. The pathological role of the non-enzymatic change of proteins by reducing sugars become frequently shows in different kinds of cancer. Cancer cells generally rely upon aerobic glycolysis as the main source of energy. Impaired glucose metabolism is somewhat responsible for the aggregation of advanced glycation end products (AGEs). Methylglyoxal (MG), a glycolysis byproduct either contributes to the accumulation of AGEs. Enzymatic defense upon AGEs products exists in all mammalian cells.
aimsThe present work intends to look into Glyoxalase1 (GLO1) and fructosamine-3-kinase (FN3K) activity in human breast carcinoma.
methodsThirty-three consecutive patients were entered into the study. Samples of breast tumoral tissue and normal matches were drawn from patients after surgery. FN3K and GLO1 enzymatic activity were analyzed using a radiometric and spectrophotometric assay.
resultsThe average level of FN3K enzyme was fundamentally lower in cancerous tissues parallel with adjacent noncancerous tissues. We also observed a consistent increase of GLO1 activity in the tumor parallel with pair-matched normal tissue.
conclusionThe current findings build up a key-role of enzymatic defense to detoxify cytotoxic AGEs and methylglyoxal levels in tumor cells. These discoveries may give another system to the treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.